Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction

14 Oct 2021

Abstract excerpt

Epithelial ovarian cancer (EOC) patients are generally diagnosed at an advanced stage, usually relapse after initial treatments, which include debulking surgery and adjuvant platinum-based chemotherapy, and eventually have poor 5-year survival of less than 50%. In recent years, promising survival benefits from maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) has changed the management...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34722237
DOI: 10.3389/fonc.2021.675972

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future DirectionPMID 34722237Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

Therapeutic applications of PARP inhibitors in ovarian cancerSemantic proximity Read ↗

Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.Semantic proximity Read ↗

Homologous recombination proficiency in ovarian and breast cancer patients.Semantic proximity Read ↗

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall SurvivalSemantic proximity Read ↗

Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor ResistanceSemantic proximity Read ↗

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP InhibitorsSemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current statusSemantic proximity Read ↗

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnosticsSemantic proximity Read ↗

Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical PerspectivesSemantic proximity Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.